675 related articles for article (PubMed ID: 23644992)
41. Efficacy of palonosetron plus aprepitant in preventing chemoradiotherapy-induced nausea and emesis in patients receiving daily low-dose cisplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a phase II study.
Hanawa S; Mitsuhashi A; Matsuoka A; Nishikimi K; Tate S; Usui H; Uno T; Shozu M
Support Care Cancer; 2016 Nov; 24(11):4633-8. PubMed ID: 27286875
[TBL] [Abstract][Full Text] [Related]
42. Palonosetron Prevents Highly Emetogenic Chemotherapy-induced Nausea and Vomiting in Oral Cancer Patients.
Sento S; Kitamura N; Yamamoto T; Nakashiro K; Hamakawa H; Ibaragi S; Sasaki A; Takamaru N; Miyamoto Y; Kodani I; Ryoke K; Mishima K; Ueyama Y;
Anticancer Res; 2017 Dec; 37(12):6977-6981. PubMed ID: 29187483
[TBL] [Abstract][Full Text] [Related]
43. A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy.
Zelek L; Debourdeau P; Bourgeois H; Wagner JP; Brocard F; Lefeuvre-Plesse C; Chauffert B; Leheurteur M; Bachet JB; Simon H; Mayeur D; Scotté F
Oncologist; 2021 Oct; 26(10):e1870-e1879. PubMed ID: 34216177
[TBL] [Abstract][Full Text] [Related]
44. Effectiveness of antiemetic triplet therapy with aprepitant, palonosetron, and dexamethasone for gynecologic cancer patients receiving carboplatin and paclitaxel: a prospective single-arm study.
Ito F; Furukawa N
Support Care Cancer; 2017 Jun; 25(6):1941-1945. PubMed ID: 28160077
[TBL] [Abstract][Full Text] [Related]
45. Effectiveness of palonosetron versus other serotonin 5-HT3 receptor antagonists in triple antiemetic regimens during multiday highly emetogenic chemotherapy.
Kim KI; Lee DE; Cho I; Yoon JH; Yoon SS; Lee HS; Oh JM
Ann Pharmacother; 2012 Dec; 46(12):1637-44. PubMed ID: 23170032
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic chemotherapy (HEC).
Karthaus M; Tibor C; Lorusso V; Singh-Arora R; Filippov A; Rizzi G; Borroni ME; Rossi G; Grunberg SM
Support Care Cancer; 2015 Oct; 23(10):2917-23. PubMed ID: 25724407
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study.
Hesketh PJ; Rossi G; Rizzi G; Palmas M; Alyasova A; Bondarenko I; Lisyanskaya A; Gralla RJ
Ann Oncol; 2014 Jul; 25(7):1340-1346. PubMed ID: 24608196
[TBL] [Abstract][Full Text] [Related]
48. A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy.
Aogi K; Sakai H; Yoshizawa H; Masuda N; Katakami N; Yanagita Y; Inoue K; Kuranami M; Mizutani M; Masuda N
Support Care Cancer; 2012 Jul; 20(7):1507-14. PubMed ID: 21808994
[TBL] [Abstract][Full Text] [Related]
49. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.
Oyama K; Fushida S; Kaji M; Takeda T; Yabushita K; Nezuka H; Kinami S; Kadoya N; Takai Y; Tsukioka Y; Ohyama S; Tsuji K; Tsukada T; Kinoshita J; Fujimura T; Ohta T
Int J Clin Oncol; 2016 Jun; 21(3):483-90. PubMed ID: 26507140
[TBL] [Abstract][Full Text] [Related]
51. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
Hajdenberg J; Grote T; Yee L; Arevalo-Araujo R; Latimer LA
J Support Oncol; 2006 Oct; 4(9):467-71. PubMed ID: 17080735
[TBL] [Abstract][Full Text] [Related]
52. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Aapro MS; Grunberg SM; Manikhas GM; Olivares G; Suarez T; Tjulandin SA; Bertoli LF; Yunus F; Morrica B; Lordick F; Macciocchi A
Ann Oncol; 2006 Sep; 17(9):1441-9. PubMed ID: 16766588
[TBL] [Abstract][Full Text] [Related]
53. Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting.
Yeh YC; McDonnell A; Klinger E; Fowler B; Matta L; Voit D; Reddy P
J Oncol Pharm Pract; 2011 Sep; 17(3):179-85. PubMed ID: 20452991
[TBL] [Abstract][Full Text] [Related]
54. A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy.
Segawa Y; Aogi K; Inoue K; Sano M; Sekine I; Tokuda Y; Isobe H; Ogura T; Tsuboi M; Atagi S;
Ann Oncol; 2009 Nov; 20(11):1874-80. PubMed ID: 19605507
[TBL] [Abstract][Full Text] [Related]
55. Clinical update on palonosetron in the management of chemotherapy-induced nausea and vomiting.
Celio L; Denaro A; Canova S; Gevorgyan A; Bajetta E
Tumori; 2008; 94(4):447-52. PubMed ID: 18822676
[TBL] [Abstract][Full Text] [Related]
56. Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study.
Rozzi A; Nardoni C; Corona M; Restuccia MR; Fabi A; Bria E; Minniti G; Lanzetta G
Support Care Cancer; 2011 May; 19(5):697-701. PubMed ID: 20467757
[TBL] [Abstract][Full Text] [Related]
57. Safety and pharmacokinetic evaluation of repeated intravenous administration of palonosetron 0.75 mg in patients receiving highly or moderately emetogenic chemotherapy.
Ikari Y; Ogata K; Nakashima Y; Sato E; Masaki M; Katsuya H; Goto T; Tanaka T; Ishitsuka K; Takamatsu Y; Hara S; Tamura K
Support Care Cancer; 2014 Jul; 22(7):1959-64. PubMed ID: 24590375
[TBL] [Abstract][Full Text] [Related]
58. Fixed combination of oral NEPA (netupitant-palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double-blind phase III studies.
Schwartzberg L; Karthaus M; Rossi G; Rizzi G; Borroni ME; Rugo HS; Jordan K; Hansen V
Cancer Med; 2019 May; 8(5):2064-2073. PubMed ID: 30968588
[TBL] [Abstract][Full Text] [Related]
59. Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapy.
Celio L; Agustoni F; Testa I; Dotti K; de Braud F
Tumori; 2012; 98(3):279-86. PubMed ID: 22825501
[TBL] [Abstract][Full Text] [Related]
60. Antiemetic efficacy of single-dose palonosetron and dexamethasone in patients receiving multiple cycles of multiple day-based chemotherapy.
Lorusso V; Giampaglia M; Petrucelli L; Saracino V; Perrone T; Gnoni A
Support Care Cancer; 2012 Dec; 20(12):3241-6. PubMed ID: 22534864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
